Takeda has signed a $268-million, 10-year pact with Japan’s Kyoto University to develop stem cell therapies for a variety of different diseases such as heart failure and cancer.

The Japanese drugs giant will work with the University’s Center for iPS Cell Research Application (CiRA) to accelerate multiple research projects using induced pluripotent stem cells as standalone treatments and in the discovery of new drugs.

Under the deal, Takeda will provide research facilities at its Shonan Research Center and collaborative funding of 20 billion yen (about $168 million) over a 10-year period, as well as more than 12 billion yen (about $100 million) worth of research support.

CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the programme, which will look at around 10 projects at a time over the 10-year period.